Fortimedix Surgical, a portfolio company of financing partners Brightlands Venture Partners (BVP) and LIOF, has been acquired by Medtronic to form Medtronic Articulating Technologies. Since their initial investment in 2016, BVP and LIOF have been continuously involved in the growth journey towards transforming medical interventions.
Related: Solventum bolsters wound care portfolio with $850m Acera Surgical acquisition
Founded as a spin-off from Fortimedix Manufacturing BV, a global leader in B2B contract stent manufacturing, Fortimedix Surgical applied its laser cutting technology to develop a range of articulating instruments for application across multiple patient therapies. In its fully equipped R&D and pilot manufacturing facility, product development and manufacturing are seamlessly integrated under one roof.
Following the acquisition, Medtronic Articulating Technologies will further develop Fortimedix’s technology to advance less invasive care, with the potential to benefit millions of patients worldwide.
BVP and LIOF were both early investors in Fortimedix Surgical. Casper Bruens and Luc Starmans, Partners at BVP: “This transaction marks the 10th successful exit within the BVP Health portfolio, showcasing our commitment to support impactful health innovations that improve patient outcomes”.
”LIOF has been supporting the company’s growth ambitions through financing from various funds, and we are proud to see it take this next step under Medtronic’s ownership”, Siska van Houdt, manager participaties & financiering LIOF.
